Beo Therapeutics ApS: Financial statements 2025
CVR: 39880377
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
Beo Therapeutics ApS (CVR 39880377) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK 0 and a net result of DKK 4,985 compared with DKK -4,910 the year before. Equity in the 2025 report amounted to DKK 40,075. The solvency ratio was 1.4%.
- Gross Profit
- DKK 0
- Profit/Loss
- DKK 4,985
- Equity
- DKK 40,075
- Total Assets
- DKK 2,787,515
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | 0 | 5K | 40K | - |
| 2024 | - | -5K | -5K | 35K | - |
| 2023 | - | - | 0 | 40K | - |
| 2022 | - | - | 0 | 40K | - |
| 2021 | - | - | 418 | 40K | - |
Official annual report
How creditworthy is Beo Therapeutics ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
Beo Therapeutics ApS has published its annual report for 2024. Gross profit came to DKK -5,000, and the net result was DKK -4,910.
About Beo Therapeutics ApS
Beo Therapeutics ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2018. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named Beo Therapeutics IVS. The management consists of Rikke Christina Nielsen. The company is owned by Rikke Christina Nielsen. The company has 1 employee (2026). In 2025, the company reported a gross profit of DKK 0 and a net result of DKK 4,985 compared with DKK -4,910 the year before. Equity in the 2025 report amounted to DKK 40,075.